Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Juergen Ramharter"'
Autor:
Norbert Kraut, Darryl B. McConnell, Mark Pearson, Timothy P. Heffernan, Mark Petronczki, Jurgen Moll, Rachel L. Mendes, Jonathan C. O'Connell, Christopher P. Vellano, Simone Lieb, Katharina Schipany, Franziska Schachinger, Nikolai Pototschnig, Jark Böttcher, Jessica L. Teh, Szu-Chin Fu, Andreas Zoephel, Tobias Wunberg, Christiane Kofink, Thomas Gerstberger, Peter Ettmayer, Dana-Adriana Botesteanu, Klaus Rumpel, Heribert Arnhof, Francesca Trapani, Dirk Kessler, Michael P. Sanderson, Joseph R. Marszalek, Daniel Gerlach, Fabio Savarese, Juergen Ramharter, Michael Gmachl, Marco H. Hofmann
Supplementary Data, Table S1, S3, S6, S8, S10-S13
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3b265e4961eac4720f5366a19b7c1c2
https://doi.org/10.1158/2159-8290.22535216
https://doi.org/10.1158/2159-8290.22535216
Autor:
Norbert Kraut, Darryl B. McConnell, Mark Pearson, Timothy P. Heffernan, Mark Petronczki, Jurgen Moll, Rachel L. Mendes, Jonathan C. O'Connell, Christopher P. Vellano, Simone Lieb, Katharina Schipany, Franziska Schachinger, Nikolai Pototschnig, Jark Böttcher, Jessica L. Teh, Szu-Chin Fu, Andreas Zoephel, Tobias Wunberg, Christiane Kofink, Thomas Gerstberger, Peter Ettmayer, Dana-Adriana Botesteanu, Klaus Rumpel, Heribert Arnhof, Francesca Trapani, Dirk Kessler, Michael P. Sanderson, Joseph R. Marszalek, Daniel Gerlach, Fabio Savarese, Juergen Ramharter, Michael Gmachl, Marco H. Hofmann
KRAS is the most frequently mutated driver of pancreatic, colorectal, and non–small cell lung cancers. Direct KRAS blockade has proved challenging, and inhibition of a key downstream effector pathway, the RAF–MEK–ERK cascade, has shown limited
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4207250379f0cc7e1fcd4e873b0d65cb
https://doi.org/10.1158/2159-8290.c.6547790.v1
https://doi.org/10.1158/2159-8290.c.6547790.v1
Autor:
Norbert Kraut, Darryl B. McConnell, Mark Pearson, Timothy P. Heffernan, Mark Petronczki, Jurgen Moll, Rachel L. Mendes, Jonathan C. O'Connell, Christopher P. Vellano, Simone Lieb, Katharina Schipany, Franziska Schachinger, Nikolai Pototschnig, Jark Böttcher, Jessica L. Teh, Szu-Chin Fu, Andreas Zoephel, Tobias Wunberg, Christiane Kofink, Thomas Gerstberger, Peter Ettmayer, Dana-Adriana Botesteanu, Klaus Rumpel, Heribert Arnhof, Francesca Trapani, Dirk Kessler, Michael P. Sanderson, Joseph R. Marszalek, Daniel Gerlach, Fabio Savarese, Juergen Ramharter, Michael Gmachl, Marco H. Hofmann
Supplementary Figures S1-S5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d96dfb43e0dbbd26e81b12152a9d88c
https://doi.org/10.1158/2159-8290.22535234
https://doi.org/10.1158/2159-8290.22535234
Autor:
Juergen Ramharter, Michael Kulhanek, Maike Dettling, Gerhard Gmaschitz, Jale Karolyi-Oezguer, Harald Weinstabl, Andreas Gollner
Publikováno v:
Organic process researchdevelopment. 26(8)
Herein, we report the structure and synthesis of the potent MDM2-p53 inhibitor BI-0282. The complex spirooxindole scaffold bearing four stereocenters embedded in a rigid polycyclic ring-system was effectively prepared on a multi-gram scale in only fi
Autor:
Andreas Gollner, Patrizia Sini, Dorothea Rudolph, Harald Weinstabl, Juergen Ramharter, Ulrike Weyer-Czernilofsky, Bojana Golubovic, Rolf Grempler, Alejandro Pérez Pitarch, Reinhard Sailer, Darryl B. McConnell, Norbert Kraut
Publikováno v:
Cancer Research. 83:LB003-LB003
The E3 ligase MDM2 controls the tumor suppressor function of p53, which is encoded by the TP53gene. Compounds designed to bind to MDM2 preventing its interaction with p53 restore the ability of p53 to combat the pathogenic processes that underly canc
Autor:
Elisabeth Grondal, Jale Karolyi-Oezguer, Dorothea Rudolph, Juergen Ramharter, Gerhard Gmaschitz, Geraldine Garavel, Joachim Broeker, Nina Kerres, Julian E. Fuchs, Patrick Werni, Karin S. Hofbauer, Wolfgang Hela, Andreas Gollner, Harald Weinstabl, Darryl B. McConnell
Publikováno v:
Chemmedchem
Mouse double minute 2 (MDM2) is a main and direct inhibitor of the crucial tumor suppressor p53. Reports from initial clinical trials showed that blocking this interaction with a small‐molecule inhibitor can have great value in the treatment of can
Autor:
Reiner Meyer, Heribert Arnhof, Daniela Haering, Rachel L Mendes, David J. Richard, Irene Weiner, Norbert Kraut, Wolfgang Hela, Christian Salamon, Klaus Rumpel, Gerd Bader, Michael Gmachl, Andreas Dr. Zöphel, Renate Schnitzer, Peter Ettmayer, Jark Böttcher, Matthew D Kennedy, Juergen Ramharter, Michael P. Sanderson, Darryl B. McConnell, Nikolai Pototschnig, Dirk Kessler, Silvia Munico-Martinez, Tobias Wunberg, Marco H. Hofmann, Katja Hauer, Thomas Gerstberger, Lyne Lamarre, Patrick Werni, Christiane Kofink, Jonathan O’Connell, Bernhard Wolkerstorfer
Publikováno v:
Journal of medicinal chemistry. 64(10)
KRAS, the most common oncogenic driver in human cancers, is controlled and signals primarily through protein-protein interactions (PPIs). The interaction between KRAS and SOS1, crucial for the activation of KRAS, is a typical, challenging PPI with a
Autor:
Szu-Chin Fu, Norbert Kraut, Rachel L Mendes, Marco H. Hofmann, Michael Gmachl, Peter Ettmayer, Katharina Schipany, Juergen Ramharter, Joseph R. Marszalek, Michael P. Sanderson, Tobias Wunberg, Fabio Savarese, Mark Petronczki, Timothy P. Heffernan, Thomas Gerstberger, Jark Böttcher, Mark Pearson, Dana-Adriana Botesteanu, Daniel Gerlach, Dirk Kessler, Franziska Schachinger, Klaus Rumpel, Jessica Teh, Jonathan O’Connell, Christiane Kofink, Heribert Arnhof, Simone Lieb, Jürgen Moll, Christopher P. Vellano, Nikolai Pototschnig, Andreas Zoephel, Darryl B. McConnell, Francesca Trapani
Publikováno v:
Cancer discovery. 11(1)
KRAS is the most frequently mutated driver of pancreatic, colorectal, and non–small cell lung cancers. Direct KRAS blockade has proved challenging, and inhibition of a key downstream effector pathway, the RAF–MEK–ERK cascade, has shown limited
Autor:
Daniel Gerlach, Thomas Gerstberger, Dirk Kessler, Tobias Wunberg, Jessica Teh, Francesca Trapani, Marco H. Hofmann, Christopher P. Vellano, Szu-Chin Fu, Mark Pearson, Joseph R. Marszalek, Heribert Arnhof, Timothy P. Heffernan, Norbert Kraut, Peter Ettmayer, Michael Gmachl, Christiane Kofink, Klaus Rumpel, Dana-Adriana Botesteanu, Darryl B. McConnell, Juergen Ramharter
Publikováno v:
Cancer Research. 80:1091-1091
KRAS is the most frequently mutated oncogene with high prevalence of alterations in pancreatic, colorectal, and non-small cell lung tumors. The alleviation of negative feedback control of KRAS activity upon downstream inhibition has limited the clini
Autor:
Johann Mulzer, Juergen Ramharter
Publikováno v:
European Journal of Organic Chemistry. 2012:2041-2053
A detailed study of the total synthesis of valerenic acid, a well known GABAA receptor subtype modulator, is described. Both successful as well as unsuccessful attempts towards the synthesis of the title compound are presented, including four differe